The Nasdaq's 5 Most Hated Stocks
The Nasdaq may be up 34% year to date, and the U.S. economy may be pointing to an ongoing recovery, but skeptics have nonetheless piled onto these five most-hated stocks.
3 Investing Lessons From Dendreon
Dendreon, the maker of the the prostate cancer drug Provenge, has been marginalized by newer drugs from Johnson & Johnson, Medivation, and Astellas Pharma. What three valuable investing lessons can investors learn from Dendreon’s mistakes?
One Person's Trash Is Another Person's Treasure Portfolio
A year-long exercise intent on proving that value and contrarian investing can be incredibly successful.